NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a $215 million Series B financing to further advance its portfolio of highly differentiated, clinical-stage, Nutrient-Stimulated Hormone (NuSH) analog peptides..

纽约--（商业新闻短讯）--Metsera，Inc.，一家临床阶段的生物制药公司，加速下一代肥胖和代谢疾病药物的开发，今天宣布结束2.15亿美元的B系列融资，以进一步推进其高度分化的临床阶段营养刺激激素（NuSH）类似肽的投资组合。。

Series B financing backed by leading mutual funds and healthcare investors

由领先的共同基金和医疗保健投资者支持的B系列融资

Wellington Management and Venrock Healthcare Capital Partners led the financing, with participation from new investors including Fidelity Management & Research Company, Janus Henderson Investors, funds and accounts advised by T. Rowe Price Associates, Inc. and by T. Rowe Price Investment Management, Inc., Viking Global Investors, Deep Track Capital, and RA Capital Management.

惠灵顿管理层和Venrock Healthcare Capital Partners领导了此次融资，新投资者包括Fidelity Management&Research Company、Janus Henderson investors、T.Rowe Price Associates，Inc.和T.Rowe Price Investment Management，Inc.、Viking Global investors、Deep Track Capital和RA Capital Management建议的基金和账户。

Existing Metsera investors, including ARCH Venture Partners, Alpha Wave Ventures, GV, SoftBank Vision Fund 2, Newpath Partners, SymBiosis, and other undisclosed investors, also participated. Metsera has raised over $500 million to date..

包括ARCH Venture Partners、Alpha Wave Ventures、GV、SoftBank Vision Fund 2、Newpath Partners、SymBiosis和其他未披露的投资者在内的现有Metsera投资者也参加了会议。到目前为止，梅瑟拉已经筹集了5亿多美元。。

Highly competitive, clinical-stage portfolio accelerating

高度竞争的临床阶段投资组合加速

Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway

正在进行超长效，完全偏倚的可注射GLP-1 RA的2期试验

Metsera recently reported significant and durable weight loss from the Phase 1/2 trial of MET-097i, a novel, fully-biased, potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.

Metsera最近报道了MET-097i的1/2期试验显着且持久的体重减轻，MET-097i是一种新型的，完全偏向的，潜在的每月一次的可注射GLP-1 RA，由Metsera的HALO™脂质化平台设计。MET-097i在第36天显示体重比基线降低了7.5%，半衰期为380小时。

Following this positive clinical data, Metsera initiated a randomized, 16-week Phase 2 trial of MET-097i in participants with obesity and overweight, with preliminary data expected in the first half of 2025. A 13-week randomized extension of the previously announced Phase 1/2 trial is also underway.

根据这一积极的临床数据，Metsera在肥胖和超重参与者中启动了一项为期16周的MET-097i随机2期试验，初步数据预计将在2025年上半年发布。之前宣布的1/2期试验的13周随机延长也正在进行中。

If these trials are successful, Metsera expects to initiate Phase 3 trials of MET-097i shortly thereafter..

。。

Ultra-long acting amylin analog clinical trial initiated

超长效胰淀素类似物临床试验启动

Metsera has initiated a single and multiple ascending dose clinical trial of MET-233i, an ultra-long acting injectable amylin analog designed for potential once-monthly dosing, in participants with obesity and overweight. MET-233i is the first of multiple next-generation NuSH analog peptides designed for combination and co-formulation with MET-097i, with matched solubility parameters and half-life.

Metsera已经启动了MET-233i的单次和多次递增剂量临床试验，MET-233i是一种超长效可注射胰淀素类似物，设计用于肥胖和超重参与者的潜在每月一次给药。MET-233i是多个下一代NuSH类似肽中的第一个，设计用于与MET-097i组合和共配制，具有匹配的溶解度参数和半衰期。

MET-233i and Metsera’s other next-generation NuSH analog peptides are also engineered with Metsera’s HALO™ lipidation platform..

。。

Oral GLP-1 RA peptide program clinical trial initiated

口服GLP-1 RA肽计划临床试验启动

Metsera has initiated a clinical trial of MET-002, an oral GLP-1 RA peptide. Metsera has developed its proprietary MOMENTUM™ platform to optimize oral delivery of NuSH analog peptides and is advancing multiple GLP-1 RA peptides with potential best-in-class bioavailability, and multiple potential first-in-class oral follow-on candidates targeting other NuSH pathways, to be developed alone and/or in combination with other NuSH analog peptides..

Metsera已经开始了口服GLP-1 RA肽MET-002的临床试验。。。

NuSH pipeline acceleration continues

NuSH管道继续加速

Metsera continues to advance multiple candidates from its proprietary peptide library, built upon approximately 20,000 NuSH analog peptides and developed through twenty years of empirical biological research and advanced peptide engineering. These candidates include MET-034i, an ultra-long acting, HALO™ lipidated GIP RA, and candidates targeting other complementary NuSH pathways, including glucagon and PYY, as well as unimolecular multi-NuSH combinations.

Metsera继续从其专有肽库中推进多种候选物，这些候选物基于大约20000个NuSH类似肽，并通过二十年的经验生物学研究和先进的肽工程开发。这些候选物包括MET-034i，一种超长效HALO™脂质化GIP-RA，以及靶向其他互补NuSH途径的候选物，包括胰高血糖素和PYY，以及单分子多NuSH组合。

Metsera is also studying combinations of these candidates..

。。

“We are excited to join a great investor syndicate to support Metsera’s differentiated portfolio of products for obesity,” said Nilesh Kumar, Head of Biotech Private Investments at Wellington Management. Nimish Shah, Partner at Venrock, added, “With an impressive management team, industry-leading peptide engineering capabilities, scaled manufacturing, and expert clinical execution, Metsera is positioned for significant value creation.”.

惠灵顿管理公司生物技术私人投资主管尼利斯·库马尔（Nilesh Kumar）表示：“我们很高兴加入一个伟大的投资者财团，支持梅瑟拉针对肥胖的差异化产品组合。”。。

“We are delighted to welcome our new Series B investors and thank existing investors for their continued support,” said Whit Bernard, Chief Executive Officer of Metsera. “Building on over twenty years of research, in the past two years Metsera has constructed a leading portfolio, initiated a large-scale manufacturing partnership, and assembled a high-performing, agile team.

Metsera首席执行官Whit Bernard表示：“我们很高兴欢迎新的B轮投资者，并感谢现有投资者的持续支持。”。“在20多年研究的基础上，梅瑟拉在过去两年中构建了一个领先的投资组合，建立了大规模的制造合作伙伴关系，并组建了一支高效、敏捷的团队。

We now have three medicines in the clinic with more to come, based on a best-in-class half-life extension technology and a potential best-in-class oral peptide delivery platform. We look forward to continued acceleration of our pipeline.”.

基于一流的半衰期延长技术和潜在的一流口服肽递送平台，我们现在在临床上有三种药物，还有更多药物。我们期待着我们的管道继续加速。”。

About MET-097i

关于MET-097i

MET-097i, Metsera’s most advanced product candidate, is a novel, fully-biased, potential once-monthly subcutaneously injectable GLP-1 RA. In September 2024, Metsera reported positive results from the Phase 1/2 trial of MET-097i. In the study, MET-097i demonstrated significant and durable weight loss, including 7.5% reduction in body weight from baseline at day 36.

Metsera最先进的候选产品MET-097i是一种新颖的，完全偏向的，潜在的每月一次皮下注射GLP-1 RA。2024年9月，Metsera报告了MET-097i 1/2期试验的阳性结果。在该研究中，MET-097i表现出显着且持久的体重减轻，包括在第36天从基线体重减轻7.5%。

MET-097i, incorporating Metsera’s HALO™ platform technology, showed a 380-hour half-life, supporting the potential for once-monthly dosing and dosing regimens without titration. Weight loss continued for at least four weeks after the last dose was administered. MET-097i is being advanced into late-stage clinical trials as a monotherapy, as well as initial clinical trials in combination with MET-233i and other NuSH analog peptide injectables..

MET-097i结合了Metsera的HALO™平台技术，显示出380小时的半衰期，支持每月一次的给药和不需要滴定的给药方案。最后一剂给药后，体重减轻持续至少四周。MET-097i正在作为单一疗法进入晚期临床试验，以及与MET-233i和其他NuSH类似肽注射剂联合进行的初步临床试验。。

About Metsera’s HALO™ peptide lipidation platform

关于Metsera的HALO™肽脂化平台

HALO™ is a novel peptide lipidation platform technology developed over 20 years of research and wholly owned by Metsera. The HALO™ approach enables peptides to bind simultaneously to albumin and to a drug target, resulting in a half-life approaching that of albumin and exceeding that of other NuSH peptides by two-to-threefold.

HALO™是一种经过20多年研究开发的新型肽脂化平台技术，由Metsera全资拥有。HALO™方法使肽能够同时与白蛋白和药物靶标结合，导致半衰期接近白蛋白的半衰期，超过其他NuSH肽的半衰期两到三倍。

This ultra-long half-life enables four key advantages: titration-free dosing, monthly dosing, improved tolerability, and improved scalability..

这种超长的半衰期具有四个关键优势：无滴定剂量，每月剂量，改善耐受性和改善可扩展性。。

About Metsera’s MOMENTUM™ oral peptide delivery platform

关于Metsera的MOMENTUM™口服肽递送平台

MOMENTUM™ is a platform for scalable delivery of oral peptides. The platform integrates multiple proprietary technologies to deliver therapeutic effects at dose levels substantially lower than competitive NuSH oral peptides, unlocking the potential for injectable-like efficacy and tolerability with similar manufacturing scale advantages to non-peptide, small molecule approaches..

MOMENTUM™是可扩展递送口服肽的平台。该平台整合了多种专有技术，以大大低于竞争性NuSH口服肽的剂量水平提供治疗效果，从而释放了类似注射的功效和耐受性的潜力，具有与非肽小分子方法相似的制造规模优势。。

About Metsera

关于梅瑟拉

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.

Metsera是一家临床阶段的生物制药公司，加速下一代肥胖和代谢疾病药物的开发。Metsera正在推进口服和注射肠降血糖素，非肠降血糖素和联合治疗的广泛组合，具有潜在的同类最佳概况，以解决多个治疗目标，并满足快速发展的减肥治疗领域的未来需求。

Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised over $500 million in financing from leading healthcare investors and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X..

Metsera由人口健康合作伙伴和ARCH Venture Partners于2022年成立，从领先的医疗保健投资者那里筹集了超过5亿美元的资金，总部位于纽约市。有关更多信息，请访问www.metsera.com，并通过LinkedIn和X关注我们。。